Not only transgenic tau mice showed suppressed neuronal activity measured with in vivo calcium imaging in the parietal cortex [8], but clinical observations from fMRI and fluordeoxyglucose-PET in human AD patients in more severe disease stages also showed cortical and hippocampal hypoactivity and hypometabolism [22, 76]. The gene discussed is MAPT; the disease is Alzheimer disease.